Saltar al contenido
Merck

Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study.

PloS one (2012-05-11)
Cédric M Hysek, Linda D Simmler, Valentina G Nicola, Nerina Vischer, Massimiliano Donzelli, Stephan Krähenbühl, Eric Grouzmann, Jörg Huwyler, Marius C Hoener, Matthias E Liechti
RESUMEN

This study assessed the effects of the serotonin (5-HT) and norepinephrine (NE) transporter inhibitor duloxetine on the effects of 3,4-methylenedioxy-methamphetamine (MDMA, ecstasy) in vitro and in 16 healthy subjects. The clinical study used a double-blind, randomized, placebo-controlled, four-session, crossover design. In vitro, duloxetine blocked the release of both 5-HT and NE by MDMA or by its metabolite 3,4-methylenedioxyamphetamine from transmitter-loaded human cells expressing the 5-HT or NE transporter. In humans, duloxetine inhibited the effects of MDMA including elevations in circulating NE, increases in blood pressure and heart rate, and the subjective drug effects. Duloxetine inhibited the pharmacodynamic response to MDMA despite an increase in duloxetine-associated elevations in plasma MDMA levels. The findings confirm the important role of MDMA-induced 5-HT and NE release in the psychotropic effects of MDMA. Duloxetine may be useful in the treatment of psychostimulant dependence. Clinicaltrials.gov NCT00990067.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Supelco
(±)-MDA solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®